Drug
Elacestrant
Elacestrant: highest development phase Phase 3, developed by Menarini. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Menarini
Trials
| Drug | Phase | Indication |
|---|---|---|
| Elacestrant NCT05512364 | Phase 3 | ER-positive Breast Cancer |
| Elacestrant NCT07242352 | Phase 3 | Breast Cancer |
Latest
No recent events.
Follow Elacestrant on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.